<DOC>
	<DOCNO>NCT01764321</DOCNO>
	<brief_summary>This prospective , post marketing , observational , Noninterventional Study ( NIS ) design compare drug persistence patient treat Certolizumab Pegol ( CZP ) patient treat subcutaneously ( sc ) administer Tumor Necrosis Factor ( TNF ) inhibitor .</brief_summary>
	<brief_title>Noninterventional Examination Subcutaneous ( sc ) Tumor Necrosis Factor ( TNF ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis ( RA ) Moderate severe disease activity RA The patient receive Tumor Necrosis Factor ( TNF ) inhibitor combination least 1 synthetic Disease Modifying Antirheumatic Drug ( DMARD ) The decision prescribe TNF inhibitor combination DMARD make treat physician , prior independently decision include patient NonInterventional Study ( NIS ) Male female patient ≥ 18 year age , consider treat physician reliable capable adhere observational plan ( eg , able understand complete questionnaire ) The patient personally sign dated Patient Data Consent Form ( PDCF ) prior Visit 2 Treatment accord Summary Product Characteristics ( SmPC ) Known contraindication Tumor Necrosis Factor ( TNF ) inhibitor Prior use TNF inhibitor ( include Adalimumab , Etanercept , Infliximab , Certolizumab , Golimumab ) , biologic DMARDs ( include Abatacept , Rituximab , Tocilizumab , Anakinra ) Participation investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>TNF inhibitor</keyword>
	<keyword>DMARD</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>